Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology’s annual meeting, but a modest survival advantage left some wondering about the clinical significance.
https://www.pharmalive.com/wp-content/uploads/2022/04/Gilead-Secures-Legal-Victory-in-Battle-Against-HIV-Drug-Fraud-BioSpace-4-20-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-06 11:58:532022-06-06 12:02:15Gilead’s Trodelvy Data Leaves Some Questioning Clinical Advantage
